Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Transplant; Complication, Rejection
Interventions
DIAGNOSTIC_TEST

Allosure

AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw

DIAGNOSTIC_TEST

AlloMap

AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.

Trial Locations (1)

10461

RECRUITING

Montefiore Medical Center, The Bronx

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CareDx

INDUSTRY

lead

Montefiore Medical Center

OTHER

NCT04855422 - Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients. | Biotech Hunter | Biotech Hunter